{"id":956837,"date":"2026-04-30T16:36:18","date_gmt":"2026-04-30T20:36:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/"},"modified":"2026-04-30T16:36:18","modified_gmt":"2026-04-30T20:36:18","slug":"trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/","title":{"rendered":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Drug\u2013drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib<\/em>\n      <\/p>\n<p>NEW HAVEN, Conn., April  30, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GUNHT4wrL48K9bkJkywfjLw9ecvIHEytdcRssH2_AqFEWkQppVdU6BQULSIspomXJVNs90JGfms_ZbFSnwQ0q7s-VZZt41zX1f_Q144Kxvxt-FWJP7fSaDIYBU_IKPYf\" rel=\"nofollow\" target=\"_blank\"><u>Trevi Therapeutics, Inc.<\/u><\/a>\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC),\u00a0today announced that it will deliver an oral presentation and present multiple abstracts at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JxdKVZvydIDvcrQibNLV0G8PG5WW2CRsKnYOSkRsafgr2emv7v3MdXG9AUxaus5926nXq77mnexwt4YwMMWAcISENdDG0XZ1Fe0DWMir6p-lyuz8eNnfpTI8GHyj0HLX7LsUoH5hRr1aB4bcJm62eCeYWwregbFqLB9f6CAuvzA=\" rel=\"nofollow\" target=\"_blank\">American Thoracic Society (ATS) 2026 International Conference<\/a>, taking place from May 15 \u2013 20, 2026, in Orlando, Florida.<\/p>\n<p><strong><u>Oral Presentation<\/u><\/strong><\/p>\n<p>\n        <strong>Abstract:<\/strong> A Phase 2b Trial (CORAL) of Nalbuphine Extended-release Tablets in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough: Primary and Subgroup Analyses<br \/><strong>Oral Presentation Session: <\/strong>B95 Fibrosis, Cough, and Inflammation: Treatment Strategies in ILD<br \/><strong>Date &amp; Time: <\/strong>May 18, 2:27 p.m. to 2:39 p.m. ET<br \/><strong>Location:<\/strong> W304 E-H (Level III, OCCC West Concourse)<br \/><strong>Presenter:<\/strong> Philip L. Molyneaux, MD, PhD<\/p>\n<p>\n        <strong><br \/>\n          <u>Poster Presentations<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Abstract:<\/strong>\u00a0Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release with Pirfenidone or Nintedanib: A Phase 1 Drug-Drug Interaction Study<br \/><strong>Poster Session:<\/strong>\u00a0\u00a0A75 Late Breaking Abstracts in Clinical Problems<br \/><strong>Date &amp; Time:\u00a0 <\/strong>May 17, 11:30 a.m. to 1:15 p.m. ET<br \/><strong>Location:\u00a0<\/strong>\u00a0Area L, Halls WA2-WA3 (Level I, OCCC West Concourse)<br \/><strong>Presenter:\u00a0<\/strong>James Cassella, PhD<\/p>\n<p>\n        <strong>Abstract:<\/strong>\u00a0The Effect of Nalbuphine Extended Release on Cough Bouts in Patients with Idiopathic Pulmonary Fibrosis from a Phase 2b Randomized Clinical Trial (CORAL)<br \/><strong>Poster Session:<\/strong> A110 Closing the Gap: Advances in Pulmonary Fibrosis<br \/><strong>Date &amp; Time:\u00a0 <\/strong>May 17, 2:15 p.m. to 4:15 p.m. ET<br \/><strong>Location:\u00a0<\/strong>\u00a0West F3 (Level II, OCCC West Concourse)<br \/><strong>Presenter: <\/strong>Jaclyn Smith, PhD, MBChB<\/p>\n<p>\n        <strong>Abstract:<\/strong>\u00a0Nalbuphine Extended Release Reduces Cough Bouts in Patients with Refractory Chronic Cough in the Phase 2a RIVER Trial<br \/><strong>Poster Session:<\/strong>\u00a0\u00a0B29 The Latest in Airway Symptoms and Disease<br \/><strong>Date &amp; Time: \u00a0<\/strong>May 18, 9:15 a.m. to 11:15 a.m. ET<br \/><strong>Location:\u00a0<\/strong>\u00a0W414AB (Level IV, OCCC West Concourse)<br \/><strong>Presenter:\u00a0<\/strong>Jaclyn Smith, PhD, MBChB<\/p>\n<p>\n        <strong>Abstract:<\/strong>\u00a0Evaluating the Burden of Chronic Cough in Patients with Interstitial Lung Disease: A US Survey-based Analysis of Its Effects on Daily Life and Emotional and Social Well-being<br \/><strong>Poster Session:<\/strong>\u00a0\u00a0B39 Breath and Burden: Diffuse Lung Diseases and Daily Life<br \/><strong>Date &amp; Time: \u00a0<\/strong>May 18, 11:30 a.m. to 1:15 p.m. ET<br \/><strong>Location:\u00a0<\/strong>\u00a0Area A, Halls WA2-WA3 (Level II, OCCC West Concourse)<br \/><strong>Presenter:\u00a0<\/strong>Jeffrey J. Swigris, DO, MS<\/p>\n<p>\n        <strong>Abstract:<\/strong>\u00a0The Effect of Nalbuphine Extended-Release Tablets on Breathlessness in Patients with Idiopathic Pulmonary Fibrosis Experiencing Chronic Cough from the Phase 2b CORAL Trial <br \/><strong>Poster Session:<\/strong>\u00a0\u00a0C103 The Next Frontier of Therapy in Pulmonary Fibrosis<br \/><strong>Date &amp; Time:\u00a0 <\/strong>May 19, 2:15 p.m. to 4:15 p.m. ET<br \/><strong>Location:\u00a0<\/strong>\u00a0West F3 (Level II, OCCC West Concourse)<br \/><strong>Presenter:\u00a0<\/strong>Donald A. Mahler, MD<\/p>\n<p>Final results from the presentations listed above will be presented at the ATS International Conference; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7GPoalTZ5uz1f69_PT57Zo2JFRackSD3vF-atx7-70qRcZWQ2ffRwNNLYuDsCwoe7v2fvbFe_UsWWBjVEBjI0cc4hKwCffTmp3wm89fs9v-oavo92LNYH-eMBvmE-RgWgq7yFdvXckUds6tEddtG0Q==\" rel=\"nofollow\" target=\"_blank\">Registration Details<\/a><\/p>\n<p>\n        <strong>About the Phase 2b CORAL Trial\u00a0 <\/strong><br \/>\n        <br \/>The Phase\u00a02b\u00a0Cough\u00a0Reduction in IPF with nalbuphine ER (CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of nalbuphine ER (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF chronic cough were randomized 1:1:1:1 to one of three nalbuphine ER dose groups or placebo with an initial 2-week titration period to the target dose followed by 4 weeks of fixed dosing. The primary efficacy endpoint for the trial was the relative change in 24-hour cough frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for nalbuphine ER compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug or placebo.\u00a0<\/p>\n<p>\n        <strong>About the Phase 2a RIVER Trial <\/strong><br \/>\n        <br \/>The Phase 2a Refractory Chronic Cough Improvement Via Nalbuphine ER (RIVER) trial was a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, and tolerability of nalbuphine ER for the treatment of patients with RCC. Each treatment period lasted 21 days, separated by a 21-day washout period. During the nalbuphine ER treatment period, patients were titrated with assessments at 27 mg twice daily (BID), 54 mg BID, and 108 mg BID for objective cough and other assessments at each dose. The primary endpoint of the trial was the mean change in 24-hour cough frequency, as determined by an objective cough monitor, for the full analysis set (FAS) population at Day 21. The FAS population included all patients who received at least one dose of study drug and have objective cough count data on both Baseline and Day 21 in at least one treatment period.<\/p>\n<p>\n        <strong>About Trevi Therapeutics, Inc.\u00a0<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a\u00a0statistically-significant\u00a0reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.\u00a0\u00a0<\/p>\n<p>Chronic\u00a0cough\u00a0in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients&#8217; quality of life.\u00a0 \u00a0\u00a0\u00a0\u00a0<br \/>\u202f\u202f\u00a0<br \/>RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting &gt;8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip)\u202fand includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.<\/p>\n<p>Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.\u00a0\u00a0\u00a0<br \/>\u202f\u202f\u00a0<br \/>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-uH3jt46-EkMwl-4NgJ2NScEdklEGYI3gSuD4KwQZFC2xtWfN6np8yogC4K2BVJQwBnXorPOsscUwWJYoK8PNEjyR4Y4GFYwh_Hq455C-sPvBWoh0Eg3hGjQhxF3Re1G\" rel=\"nofollow\" target=\"_blank\"><u>www.TreviTherapeutics.com<\/u><\/a>\u00a0and follow Trevi on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z6fYkN380PPigLFAzkdvd8xAYt8ZdSW8Giz_HVjxHCIrlxx2OQ7PomNmvtEvlHj9_Rp8q0CcwvsCC0Z3zJi2WA==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>\u00a0(formerly Twitter) and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JIr70QB9m7VAPjUOuh4d0iwzcZOFsA6bt7Hp05oiYI0HAPE44gTh83RUtEOW4SXJUiHbPUn7nLwuFhbPoLVa7vsJnIUtCGsRETIC0O_cqVDJspGkuIl5lfKhcnQPB6ek\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.\u00a0\u00a0\u00a0<br \/>\u202f\u00a0<br \/><strong>Investor Contact<\/strong>\u00a0\u00a0\u00a0 <br \/>Jonathan Carlson\u00a0\u00a0\u00a0 <br \/>Trevi Therapeutics, Inc.\u00a0\u00a0\u00a0 <br \/>(203) 654 3286\u00a0\u00a0\u00a0 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VzoA94VFBr7u_tQU8sykqQVSV2GDSe3sSuDY3bN7GmmnLJEk5RBoY0ubyWWpGr3N5edSbHQ3OfeC6LbooeucAQ==\" rel=\"nofollow\" target=\"_blank\">IR@trevitx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>\u00a0\u00a0\u00a0 <br \/>Rosalia Scampoli\u00a0\u00a0\u00a0 <br \/>914-815-1465\u00a0\u00a0\u00a0 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XkgTctNgCbR3QXrKQtkGdpIADN3v4ODSDGwJCSTbIEFS9sfhZIzkmoKqY57RKWjQIh_P-GK8B-sGSBFntIexvotrU7tRr0DO5CvmvecLRjrCLEnuz5rRUhPRQbI7ihTT\" rel=\"nofollow\" target=\"_blank\">rscampoli@marketcompr.com<\/a>\u00a0\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWE0MTI1NTAtZjFjZS00NjgyLWE1NDItZThiOGVmZTYzOTQ1LTExMzY2ODctMjAyNi0wNC0zMC1lbg==\/tiny\/Trevi-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug\u2013drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0oral nalbuphine ER for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-956837","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug\u2013drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0oral nalbuphine ER for &hellip; Continue reading &quot;Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T20:36:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference\",\"datePublished\":\"2026-04-30T20:36:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/\"},\"wordCount\":1229,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/\",\"name\":\"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=\",\"datePublished\":\"2026-04-30T20:36:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - Market Newsdesk","og_description":"Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug\u2013drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI),\u00a0a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0oral nalbuphine ER for &hellip; Continue reading \"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-30T20:36:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference","datePublished":"2026-04-30T20:36:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/"},"wordCount":1229,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/","name":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=","datePublished":"2026-04-30T20:36:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMDc5MSM3NTc2NjMyIzIxMjUxMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-announces-oral-presentation-and-multiple-posters-accepted-at-the-american-thoracic-society-ats-2026-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=956837"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956837\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=956837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=956837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=956837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}